Perspectives on replication-incompetent nasal influenza virus vaccines

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 907-909

  Tang, De Chu C ^a  

^a Vaxin Incorporated   (United States)

Author keywords

influenza virus vaccine; nasal influenza vaccine; PB2 knockout influenza virus; replication incompetent influenza virus

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; BIOENGINEERING; CONTROLLED STUDY; GENE EXPRESSION; IMMUNE RESPONSE; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TRANSGENE; VIRUS PARTICLE; VIRUS STRAIN;

EID: 84866653715     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.64     Document Type: Review

References (12)

1. Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 333(14), 889-893 (1995).
2. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev. Vaccines 8(4), 469-481 (2009).
3. Zhang J, Tarbet EB, Toro H, Tang DC. Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases. Expert Rev. Vaccines 10(11), 1539-1552 (2011).
4. Bodewes R, Fraaij PL, Geelhoed-Mieras MM et al. Annual vaccination against influenza virus hampers development of virus-specific CD8+ T cell immunity in children. J. Virol. 85(22), 11995-12000 (2011).
5. Hilleman MR. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 20(25-26), 3068-3087 (2002).
6. Victor ST, Watanabe S, Katsura H, Ozawa M, Kawaoka Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J. Virol. 86(8), 4123-4128 (2012).
7. Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl Acad. Sci. USA 96(16), 9345-9350 (1999).
8. Zhou B, Li Y, Belser JA et al. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 28(50), 8015-8025 (2010).
9. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replicationincompetent influenza virus-like particles. J. Virol. 76(2), 767-773 (2002).
10. Mueller S, Coleman JR, Papamichail D et al. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 28(7), 723-726 (2010).
11. Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, Tang DC. Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLoS ONE 6(7), e22605 (2011).
12. Seo SU, Lee KH, Byun YH, Kweon MN, Seong BL. Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine. Vaccine 25(47), 8067-8076 (2007).